Osteopore Ltd (OSX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Osteopore Ltd (OSX) has a cash flow conversion efficiency ratio of 3.011x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.28 Million ≈ $-902.50K USD) by net assets (AU$-423.65K ≈ $-299.76K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Osteopore Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Osteopore Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Osteopore Ltd total liabilities for a breakdown of total debt and financial obligations.
Osteopore Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Osteopore Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tristel
LSE:TSTL
|
0.161x |
|
Foresight Autonomous Holdings Ltd
TA:FRSX
|
-0.464x |
|
Enorama Pharma AB
ST:ERMA
|
0.631x |
|
Mdundo Com As
CO:MDUNDO
|
-0.275x |
|
Bone Biologics Corp
NASDAQ:BBLG
|
-0.098x |
|
PBS Finanse SA
WAR:PBF
|
-0.096x |
|
Olivut Resources Ltd
V:OLV
|
-0.350x |
|
ModuLink Inc.
NASDAQ:MDLK
|
-2.896x |
Annual Cash Flow Conversion Efficiency for Osteopore Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Osteopore Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Osteopore Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$306.22K ≈ $216.67K |
AU$-3.09 Million ≈ $-2.18 Million |
-10.084x | -16.73% |
| 2023-12-31 | AU$432.60K ≈ $306.09K |
AU$-3.74 Million ≈ $-2.64 Million |
-8.639x | -355.31% |
| 2022-12-31 | AU$2.11 Million ≈ $1.49 Million |
AU$-4.00 Million ≈ $-2.83 Million |
-1.897x | -167.87% |
| 2021-12-31 | AU$5.37 Million ≈ $3.80 Million |
AU$-3.81 Million ≈ $-2.69 Million |
-0.708x | -262.52% |
| 2020-12-31 | AU$9.00 Million ≈ $6.37 Million |
AU$-1.76 Million ≈ $-1.24 Million |
-0.195x | +66.85% |
| 2019-12-31 | AU$2.97 Million ≈ $2.10 Million |
AU$-1.75 Million ≈ $-1.24 Million |
-0.589x | -646.63% |
| 2018-12-31 | AU$4.23 Million ≈ $3.00 Million |
AU$-334.12K ≈ $-236.41K |
-0.079x | -1197.74% |
| 2017-12-31 | AU$-1.84 Million ≈ $-1.30 Million |
AU$11.16K ≈ $7.90K |
-0.006x | -104.48% |
| 2016-12-31 | AU$-1.36 Million ≈ $-959.71K |
AU$-184.27K ≈ $-130.38K |
0.136x | -- |
About Osteopore Ltd
Osteopore Limited, a regenerative medicine company, engages in the production of 3D-printed biomimetic and bioresorbable implants in Vietnam, South Korea, the Philippines, Singapore, India, Malaysia, the Netherlands, Thailand, Australia, and internationally. The company commercializes products designed to enable natural bone healing across multiple therapeutic areas. Its technology fabricates spe… Read more